Literature DB >> 16532490

Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease.

Tokiko Fukuda1, Lindsay Ewan, Martina Bauer, Robert J Mattaliano, Kristien Zaal, Evelyn Ralston, Paul H Plotz, Nina Raben.   

Abstract

OBJECTIVE: To understand the mechanisms of skeletal muscle destruction and resistance to enzyme replacement therapy in Pompe disease, a deficiency of lysosomal acid alpha-glucosidase (GAA), in which glycogen accumulates in lysosomes primarily in cardiac and skeletal muscles.
METHODS: We have analyzed compartments of the lysosomal degradative pathway in GAA-deficient myoblasts and single type I and type II muscle fibers isolated from wild-type, untreated, and enzyme replacement therapy-treated GAA knock-out mice.
RESULTS: Studies in myoblasts from GAA knock-out mice showed a dramatic expansion of vesicles of the endocytic/autophagic pathways, decreased vesicular movement in overcrowded cells, and an acidification defect in a subset of late endosomes/lysosomes. Analysis by confocal microscopy of isolated muscle fibers demonstrated that the consequences of the lysosomal glycogen accumulation are strikingly different in type I and II muscle fibers. Only type II fibers, which are the most resistant to therapy, contain large regions of autophagic buildup that span the entire length of the fibers.
INTERPRETATION: The vastly increased autophagic buildup may be responsible for skeletal muscle damage and prevent efficient trafficking of replacement enzyme to lysosomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16532490     DOI: 10.1002/ana.20807

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  107 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders.

Authors:  Alessandro Fraldi; Fabio Annunziata; Alessia Lombardi; Hermann-Josef Kaiser; Diego Luis Medina; Carmine Spampanato; Anthony Olind Fedele; Roman Polishchuk; Nicolina Cristina Sorrentino; Kai Simons; Andrea Ballabio
Journal:  EMBO J       Date:  2010-09-24       Impact factor: 11.598

Review 3.  Glycogen phosphorylation and Lafora disease.

Authors:  Peter J Roach
Journal:  Mol Aspects Med       Date:  2015-08-13

Review 4.  Role of autophagy in the pathogenesis of Pompe disease.

Authors:  N Raben; A Roberts; P H Plotz
Journal:  Acta Myol       Date:  2007-07

5.  Monitoring autophagy in lysosomal storage disorders.

Authors:  Nina Raben; Lauren Shea; Victoria Hill; Paul Plotz
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 6.  Autophagy and neurodegeneration.

Authors:  Annamaria Ventruti; Ana Maria Cuervo
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

7.  mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy.

Authors:  James K Ching; Sarita V Elizabeth; Jeong-Sun Ju; Caleb Lusk; Sara K Pittman; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

Review 8.  Mechanisms for fiber-type specificity of skeletal muscle atrophy.

Authors:  Yichen Wang; Jeffrey E Pessin
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-05       Impact factor: 4.294

9.  Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.

Authors:  Baodong Sun; Sarah P Young; Ping Li; Chunhui Di; Talmage Brown; Maja Z Salva; Songtao Li; Andrew Bird; Zhen Yan; Richard Auten; Stephen D Hauschka; Dwight D Koeberl
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

10.  Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy.

Authors:  A Broomfield; J Fletcher; J Davison; N Finnegan; M Fenton; A Chikermane; C Beesley; K Harvey; E Cullen; C Stewart; S Santra; S Vijay; M Champion; L Abulhoul; S Grunewald; A Chakrapani; M A Cleary; S A Jones; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2015-10-26       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.